Format

Send to

Choose Destination
Child Adolesc Psychiatr Clin N Am. 2012 Oct;21(4):941-55. doi: 10.1016/j.chc.2012.07.005.

Pharmacotherapy of pediatric attention-deficit/hyperactivity disorder.

Author information

1
Department of Psychiatry, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, NE 68198-5581, USA.

Abstract

This article describes the practical use of available attention-deficit/hyperactivity disorder (ADHD) pharmacotherapies, their formulations and durations of action, and the extent of Food and Drug Administration approvals. It provides data on short-term and long-term safety of these medications, their use in ADHD with comorbid conditions, and strategies for formulating individualized, effective, and well-tolerated pharmacotherapy treatment plans. A clinical vignette focusing on a male child with ADHD is presented. Summaries are presented of ADHD pharmacotherapies and Food and Drug Administration approval status, atomoxetine and stimulant comparator trials, adverse effects and ADHD pharmacotherapy, and delivery system and duration of effect.

PMID:
23040908
DOI:
10.1016/j.chc.2012.07.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center